AU2006334733A1 - Combination of triazine derivatives and HMG-COA reductase inhibitors for the treatment of diabetes - Google Patents
Combination of triazine derivatives and HMG-COA reductase inhibitors for the treatment of diabetes Download PDFInfo
- Publication number
- AU2006334733A1 AU2006334733A1 AU2006334733A AU2006334733A AU2006334733A1 AU 2006334733 A1 AU2006334733 A1 AU 2006334733A1 AU 2006334733 A AU2006334733 A AU 2006334733A AU 2006334733 A AU2006334733 A AU 2006334733A AU 2006334733 A1 AU2006334733 A1 AU 2006334733A1
- Authority
- AU
- Australia
- Prior art keywords
- alkoxy
- alkyl
- amino
- aryl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0600343A FR2896158B1 (fr) | 2006-01-13 | 2006-01-13 | Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase. |
| FR06/00343 | 2006-01-13 | ||
| PCT/EP2006/012184 WO2007079916A2 (en) | 2006-01-13 | 2006-12-18 | Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2006334733A1 true AU2006334733A1 (en) | 2007-07-19 |
Family
ID=36649749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006334733A Abandoned AU2006334733A1 (en) | 2006-01-13 | 2006-12-18 | Combination of triazine derivatives and HMG-COA reductase inhibitors for the treatment of diabetes |
Country Status (14)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US8722674B2 (en) | 2007-08-31 | 2014-05-13 | Hanall Biopharma Co., Ltd. | 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same |
| JP5485292B2 (ja) * | 2008-12-12 | 2014-05-07 | ポクセル・エスアーエス | Ampk活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物 |
| FR2948028B1 (fr) * | 2009-07-17 | 2011-12-02 | Merck Sante Sas | Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine |
| EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
| MY203360A (en) | 2018-06-06 | 2024-06-26 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
| CA3103324A1 (en) | 2018-06-14 | 2019-12-19 | Poxel | Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes |
| KR20220113942A (ko) * | 2019-12-13 | 2022-08-17 | 스미토모 파마 가부시키가이샤 | 제조성 및 용출성이 우수한 소형 정제 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3651816B2 (ja) * | 1995-07-03 | 2005-05-25 | 三共株式会社 | 動脈硬化症予防および治療剤 |
| FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
| FR2853650B1 (fr) * | 2003-04-10 | 2006-07-07 | Merck Sante Sas | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance |
| EP1510208A1 (en) * | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
-
2006
- 2006-01-13 FR FR0600343A patent/FR2896158B1/fr not_active Expired - Fee Related
- 2006-12-18 AU AU2006334733A patent/AU2006334733A1/en not_active Abandoned
- 2006-12-18 CN CNA2006800508489A patent/CN101355935A/zh active Pending
- 2006-12-18 BR BRPI0621420-7A patent/BRPI0621420A2/pt not_active IP Right Cessation
- 2006-12-18 EP EP06829705A patent/EP1978951A2/en not_active Withdrawn
- 2006-12-18 JP JP2008549782A patent/JP2009523141A/ja active Pending
- 2006-12-18 CA CA002636840A patent/CA2636840A1/en not_active Abandoned
- 2006-12-18 KR KR1020087019392A patent/KR20080085208A/ko not_active Withdrawn
- 2006-12-18 EA EA200801666A patent/EA200801666A1/ru unknown
- 2006-12-18 WO PCT/EP2006/012184 patent/WO2007079916A2/en not_active Ceased
- 2006-12-18 US US12/160,504 patent/US20100158999A1/en not_active Abandoned
-
2007
- 2007-01-12 AR ARP070100137A patent/AR059031A1/es unknown
-
2008
- 2008-07-02 IL IL192594A patent/IL192594A0/en unknown
- 2008-08-12 ZA ZA200806937A patent/ZA200806937B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101355935A (zh) | 2009-01-28 |
| FR2896158B1 (fr) | 2008-09-12 |
| WO2007079916A3 (en) | 2007-12-06 |
| CA2636840A1 (en) | 2007-07-19 |
| FR2896158A1 (fr) | 2007-07-20 |
| EA200801666A1 (ru) | 2008-12-30 |
| US20100158999A1 (en) | 2010-06-24 |
| WO2007079916A2 (en) | 2007-07-19 |
| ZA200806937B (en) | 2009-07-29 |
| BRPI0621420A2 (pt) | 2011-12-06 |
| AR059031A1 (es) | 2008-03-12 |
| JP2009523141A (ja) | 2009-06-18 |
| IL192594A0 (en) | 2009-09-22 |
| KR20080085208A (ko) | 2008-09-23 |
| EP1978951A2 (en) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI407955B (zh) | 高脂血症之預防及/或治療劑 | |
| US20140050786A1 (en) | Combination of triazine derivatives and insulin sensitisers | |
| AU2004266070A1 (en) | Pharmaceutical composition comprising a combination of metformin and a statin | |
| US20100158999A1 (en) | Combination of triazine derivatives and hmg-coa reductase inhibitors | |
| EP1971339B1 (en) | Combination of triazine derivatives and insulin secretion stimulators | |
| MX2008008887A (en) | Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes | |
| HK1128231A (en) | Combination of triazine derivatives and hmg-coa reductase inhibitors for the treatment of diabetes | |
| AU2006334735A1 (en) | Combination of triazine derivatives and PPAR&agr;agonists | |
| HK1128233A (en) | COMBINATION OF TRIAZINE DERIVATIVES AND PPARα AGONISTS | |
| MX2008008895A (en) | Combination of triazine derivatives and insulin sensitisers | |
| HK1128232A (en) | Combination of triazine derivatives and insulin sensitisers | |
| MX2008008894A (en) | Combination of triazine derivatives and insulin secretion stimulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: POXEL SAS Free format text: FORMER APPLICANT(S): MERCK PATENT GMBH |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |